A new NCI-funded initiative is set to investigate the biological processes behind breast cancer relapse and dormancy following a $10 million award. The project will be led by Julio A. Aguirre-Ghiso and aims to map mechanisms that allow disseminated tumor cells to remain inactive and later restart. The grant underscores ongoing emphasis on understanding relapse biology rather than focusing only on treatment response. For translational teams, the work is likely to inform biomarker development and new interventions aimed at preventing late recurrence. While details of the specific scientific approach are not provided in the summary, the move highlights dormancy as a priority target area for future therapeutic discovery programs. In parallel with broader relapse-focused research, the funding signals continued institutional support for mechanism-driven strategies in difficult-to-treat disease trajectories.